# Lung Cancer Staging and Surgical Indications

## Overview

Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of cases, with small cell lung cancer (SCLC) comprising the remaining 15%. The major NSCLC subtypes are adenocarcinoma (the most common), squamous cell carcinoma, and large cell carcinoma. Surgical resection remains the cornerstone of curative therapy for early-stage NSCLC, and accurate staging is essential for treatment planning and prognosis.

## TNM Staging System (8th Edition)

### T (Primary Tumor)

The T descriptor classifies the primary tumor by size and extent of invasion. **Tis** denotes carcinoma in situ or adenocarcinoma in situ. **T1** tumors are 3 cm or smaller, further divided into T1a(mi) for minimally invasive adenocarcinoma, T1a for tumors 1 cm or smaller, T1b for tumors greater than 1 cm to 2 cm, and T1c for tumors greater than 2 cm to 3 cm. **T2** tumors measure greater than 3 cm to 5 cm, or involve the main bronchus (not the carina), invade the visceral pleura, or cause atelectasis or pneumonitis extending to the hilum; T2a covers tumors greater than 3 cm to 4 cm and T2b covers tumors greater than 4 cm to 5 cm. **T3** tumors measure greater than 5 cm to 7 cm, or invade the chest wall, phrenic nerve, or parietal pericardium, or represent a separate tumor nodule in the same lobe. **T4** tumors exceed 7 cm, or invade the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina, or include a separate nodule in a different ipsilateral lobe.

### N (Regional Lymph Nodes)

**N0** indicates no regional lymph node metastasis. **N1** denotes ipsilateral peribronchial and/or hilar node involvement. **N2** denotes ipsilateral mediastinal and/or subcarinal node involvement. **N3** indicates contralateral mediastinal or hilar nodes, or ipsilateral or contralateral scalene or supraclavicular nodes.

### M (Distant Metastasis)

**M0** indicates no distant metastasis. **M1a** includes separate tumor nodules in the contralateral lobe, pleural or pericardial nodules, or malignant pleural or pericardial effusion. **M1b** denotes a single extrathoracic metastasis. **M1c** denotes multiple extrathoracic metastases in one or more organs.

<image>TNM staging diagram for lung cancer showing T descriptors with size thresholds and anatomic invasion criteria</image>

## Stage Groupings and 5-Year Survival

### Stage Groupings and 5-Year Survival

| Stage | TNM | 5-Year Survival |
|-------|-----|-----------------|
| IA1-IA3 | T1a-T1c N0 M0 | 77-92% |
| IB | T2a N0 M0 | 68% |
| IIA | T2b N0 M0 | 60% |
| IIB | T1-T2 N1 or T3 N0 | 53% |
| IIIA | T1-T2 N2, T3 N1, T4 N0-N1 | 36% |
| IIIB | T1-T2 N3, T3-T4 N2 | 26% |
| IIIC | T3-T4 N3 | 13% |
| IVA | Any T, any N, M1a-M1b | 10% |
| IVB | Any T, any N, M1c | 0-6% |

Stage groupings correlate with survival. **Stage IA1-IA3** (T1a-T1c N0 M0) carries a 77-92% 5-year survival. **Stage IB** (T2a N0 M0) is 68%. **Stage IIA** (T2b N0 M0) is 60%. **Stage IIB** (T1-T2 N1 or T3 N0) is 53%. **Stage IIIA** (T1-T2 N2, T3 N1, T4 N0-N1) is 36%. **Stage IIIB** (T1-T2 N3, T3-T4 N2) is 26%. **Stage IIIC** (T3-T4 N3) is 13%. **Stage IVA** (any T, any N, M1a-M1b) is 10%. **Stage IVB** (any T, any N, M1c) is 0-6%.

## Preoperative Workup

### Imaging

**CT chest with contrast** provides anatomic assessment of the tumor, lymph nodes, and adjacent structures. **PET-CT** offers metabolic staging with sensitivity of approximately 80% and specificity of approximately 90% for mediastinal nodes; an SUV greater than 2.5 is generally considered suspicious but not diagnostic. False positives occur with infection, inflammation, and granulomatous disease, while false negatives occur with low-grade tumors (ground glass opacities, carcinoid) and small lesions (less than 8 mm). **Brain MRI** is recommended for stage IB and above (CT head if MRI is unavailable). **Bone scan** is rarely needed if PET-CT has been performed.

### Tissue Diagnosis

CT-guided transthoracic needle biopsy is appropriate for peripheral lesions, while bronchoscopy with biopsy is used for central lesions. Navigational bronchoscopy reaches intermediate lesions. EBUS-TBNA provides mediastinal and hilar lymph node sampling. In some cases, surgical diagnosis at the time of resection is appropriate for small peripheral nodules with high clinical suspicion.

### Mediastinal Staging

Mediastinal staging is critical for treatment planning because upstaging to N2 changes management. **Non-invasive** assessment with PET-CT serves as a screening tool but is not definitive. **Minimally invasive** techniques include EBUS-TBNA (accessing stations 2R, 2L, 4R, 4L, 7, 10, 11) and EUS-FNA (accessing stations 7, 8, 9 and left-sided nodes); combined EBUS/EUS provides the most comprehensive assessment. **Invasive** approaches include cervical mediastinoscopy (the gold standard for stations 2R, 2L, 4R, 4L, 7), the Chamberlain procedure (anterior mediastinotomy for stations 5 and 6), and VATS for direct visualization and biopsy. Guidelines require invasive confirmation when PET-positive mediastinal nodes or central tumors are present.

<image>Mediastinal lymph node station map (IASLC) showing numbered stations and their anatomic relationships to bronchi and great vessels</image>

## Physiologic Assessment for Surgical Candidacy

### Pulmonary Function

Spirometry with FEV1 and DLCO are the key parameters. Predicted postoperative (ppo) values guide decisions: ppoFEV1 greater than 40% predicted is generally acceptable for lobectomy, ppoFEV1 greater than 30% may tolerate surgery with increased risk, and ppoDLCO greater than 40% is generally acceptable. A quantitative perfusion lung scan calculates segment-based ppo values.

### Physiologic Assessment Thresholds for Surgical Candidacy

| Parameter | Low Risk | Moderate Risk | Prohibitive Risk |
|-----------|----------|---------------|------------------|
| ppoFEV1 | > 40% predicted | 30-40% predicted | < 30% predicted |
| ppoDLCO | > 40% predicted | 30-40% predicted | < 30% predicted |
| VO2max | > 20 mL/kg/min | 10-20 mL/kg/min | < 10 mL/kg/min |

### Cardiopulmonary Exercise Testing

VO2max is the best predictor of operative risk. VO2max greater than 20 mL/kg/min indicates low risk. VO2max of 10-20 mL/kg/min indicates moderate risk requiring case-by-case decision-making. VO2max less than 10 mL/kg/min indicates prohibitive risk for major resection.

### Cardiac Assessment

Cardiac risk factors and functional status are assessed. The Revised Cardiac Risk Index (RCRI) guides the need for further testing. Echocardiography is obtained if there is clinical suspicion of valvular or ventricular dysfunction, and coronary evaluation is pursued for active cardiac symptoms.

## Surgical Indications by Stage

### Stage I-II (N0-N1)

Primary surgical resection is the standard of care. Anatomic lobectomy with systematic mediastinal lymph node dissection is the gold standard. Sublobar resection (segmentectomy) is now accepted for tumors 2 cm or smaller in peripheral NSCLC, based on the JCOG0802 and CALGB 140503 trials. Adjuvant chemotherapy is standard for stage II and considered for high-risk IB (tumor greater than 4 cm, lymphovascular invasion, poorly differentiated histology).

### Stage IIIA (N2 Disease)

This is a heterogeneous group whose management depends on the extent of N2 involvement. **Single-station, non-bulky N2** disease is managed with neoadjuvant chemotherapy (with or without immunotherapy) followed by surgery. **Bulky or multi-station N2** disease is generally treated with definitive chemoradiation, though surgery may be considered in selected patients after induction therapy with restaging. Multidisciplinary tumor board discussion is essential.

### Stage IIIB-IV

These patients are generally not surgical candidates. An emerging role exists for surgery in **oligometastatic disease** (M1b) combined with systemic therapy in highly selected patients. A **solitary brain metastasis** with a resectable primary may be considered for craniotomy followed by lung resection.

<image>Algorithm for lung cancer workup and surgical decision-making from initial imaging through mediastinal staging to physiologic assessment and treatment selection</image>

## Lymph Node Assessment at Surgery

**Systematic mediastinal lymph node dissection** — removal of all nodes from stations 2R, 4R, 7, 8, 9 on the right side or stations 5, 6, 7, 8, 9 on the left side — is superior to lymph node sampling for accurate staging. A minimum of 3 N2 stations should be sampled, and NCCN recommends dissection. A total lymph node count of 10-12 or more is associated with more accurate staging. Intraoperative frozen section of suspicious nodes may alter the surgical plan.

## Clinical Pearls

PET-CT is a screening tool for mediastinal disease, not a definitive staging modality — always confirm PET-positive N2 nodes with tissue sampling before denying a patient surgery. Ground glass-predominant adenocarcinomas often have low PET avidity, and PET alone should not be relied upon. Brain MRI should be obtained in all patients stage IB and above because brain metastases change everything. Predicted postoperative FEV1 and DLCO below 40% predicted are not absolute contraindications but require careful shared decision-making and cardiopulmonary exercise testing. Multidisciplinary tumor board discussion is the standard of care for all lung cancer patients, especially stage III. Operating without adequate mediastinal staging should never occur — unexpected N2 disease at surgery represents a staging failure.

## References

- Goldstraw P et al. "The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings (8th Edition)." *J Thorac Oncol*. 2016.
- Silvestri GA et al. "Methods for Staging Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer (3rd Edition), ACCP Guidelines." *Chest*. 2013.
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2024.
- Brunelli A et al. "ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients." *Eur Respir J*. 2009.
- Detterbeck FC et al. "Invasive Mediastinal Staging of Lung Cancer." *Chest*. 2007.